News | PET-CT | September 13, 2017

Blue Earth Diagnostics Announcing Results of FALCON PET/CT Trial at ASTRO 2017

Trial assessed the impact of F-18 PET/CT on patient management in biochemically recurrent prostate cancer patients scheduled for salvage treatment with curative intent

Blue Earth Diagnostics Announcing Results of FALCON PET/CT Trial at ASTRO 2017

September 13, 2017 — Blue Earth Diagnostics announced the upcoming oral presentation of initial results from the FALCON clinical trial of fluciclovine (18F) positron emission tomography/computed tomography (PET/CT) at the 2017 American Society for Radiation Oncology (ASTRO) annual meeting Sept. 24-27 in San Diego. The FALCON trial evaluated the impact of F-18 PET/CT on patient management in biochemically recurrent prostate cancer patients scheduled for salvage radiation therapy treatment with curative intent. Trial results will be presented by Eugene Teoh, M.D., Oxford University Hospitals NHS Trust, Oxford, U.K.

Blue Earth Diagnostics is also hosting an Industry-Expert Theater event, “A Novel Option for Biochemically Recurrent Prostate Cancer Localization,” with invited speaker Abhishek Solanki, M.D., assistant professor of radiation oncology, Loyola University School of Medicine, Chicago, which will be held on Tuesday, Sept. 26.

For more information: www.blueearthdiagnostics.com

Related Content

Axumin PET Agent Added to NCCN Guidelines for Suspected Recurrent Prostate Cancer
News | PET Imaging | February 21, 2018
Blue Earth Diagnostics announced that Axumin (fluciclovine F 18) injection has been added to the National Comprehensive...
Radiography Education Enrollment Shows Marginal Rise in 2017
News | Business | February 15, 2018
Directors of radiography educational programs report the number of enrolled students increased slightly in 2017, while...
Patients Lack Information About Imaging Exams
News | Patient Engagement | February 14, 2018
Patients and their caregivers desire information about upcoming imaging examinations, but many are not getting it,...
A Tc99m SPECT cardiac exam showing myocardial perfusion in the heart.

Technetium-99m is primarily used for the detection of cancer and to assess perfusion defects in the heart caused by heart attacks or other conditions.

Feature | Radiopharmaceuticals and Tracers | February 08, 2018 | Dave Fornell
February 8, 2018 — The U.S.
PSMA PET-CT Clearly Differentiates Prostate Cancer from Benign Tissue

68Ga-PSMA PET/CT images showing multifocal PCA in peripheral zone with GS of 5 1 5 5 10. (A and C) Axial PET images. (B and D) Fused PET/CT images. SUVmax of lesion in B was 84.3 and that of lesion in D was 5.7. IRS was 3, and 80% of cells were stained. Credit: Senior author V Prasad, Charité Universitätsmedizin Berlin, Berlin, Germany.

News | PET-CT | February 05, 2018
February 5, 2018 — Using nuclear medicine...

This PET/CT shows metastasis of tumors, taken with the Philips TruFlight Select.

Feature | Radiation Oncology | January 31, 2018 | By Emily Clemons
Technological and scientific advances in radiation oncology are allowing practitioners to put patients first in...
Small-Cell Lung Cancer Patients Face Barriers to Standard-of-Care Treatment
News | Lung Cancer | January 29, 2018
Despite decades of clinical research establishing chemotherapy with thoracic radiation as the standard-of-care for the...
Advaxis Immunotherapy Offers Potential Combo Treatment for Anal Cancer
News | Radiation Therapy | January 26, 2018
January 26, 2018 — Advaxis Inc.
Brain-scan guided emergency stroke treatment can save more lives
News | Neuro Imaging | January 25, 2018
January 25, 2018 – Advances in brain imagin...
Overlay Init